Differences in first-line chemosensitivity assessed by ELIMination rate constant K in advanced serous ovarian cancer: evidence from Western and Japanese Trials in a Gynecologic Cancer InterGroup meta-analysis

International Journal of Gynecological Cancer 2026 Open access

Read full text
Authors: Pauline Corbaux, Benoît You, Iain McNeish, Stephen Welch, Anna V. Tinker, Mansoor R. Mirza, Kristina Lindemann, Tatsuo Kagimura, Isabelle L. Ray-Coquard, Fabien Subtil, Julien Péron, Karen Carty
+7 more Caroline Kelly, Olivier Colomban, Eleni Karamouza, Adrian Cook, Xavier Paoletti, Rosalind Margaret Glasspool, Nozomu Yanaihara
DOI: 10.1016/j.ijgc.2026.104805
Cited by: 1
References: 45

Abstract

OBJECTIVE: Growing evidence suggests potential ethnic and geographical variations in chemotherapy efficacy. The CA125 ELIMination rate constant K score is a pragmatic and reproducible indicator of tumor chemosensitivity in newly diagnosed ovarian cancer. We compared ELIMination rate constant K distributions and prognostic performances between patients enrolled in Japanese and Western trials who had stage III/IV serous ovarian cancer from the Gynecologic Cancer InterGroup individual-patient-data Meta-Analysis in OVarian cancer. METHODS: The ELIMination rate constant K values were previously estimated for 5884 women receiving first-line chemotherapy for ovarian cancer. Data from 246 women enrolled in the Japanese JGOG-3016 trial were compared to 2561 patients from Western trials. ELIMination rate constant K was analyzed as a binary variable (favorable ≥1.0 vs unfavorable

Fields of Study & Subjects

Ovarian cancer diagnosis and treatment Endometrial and Cervical Cancer Treatments PARP inhibition in cancer therapy

Publication details

Journal / source
International Journal of Gynecological Cancer
Publisher
Elsevier BV
Volume
36
Issue
9
Pages
104805–104805
Publication date
16 June 2026
Language
EN